Clovis Oncology (CLVS)

Add to Watchlists Create an Alert
33.50 +0.21  +0.63%   NASDAQ May 23, 8:00PM BATS Real time Currency in USD

Clovis Oncology SG&A Expense Quarterly:

3.218M for Dec. 31, 2012
View Full Chart

Clovis Oncology SG&A Expense Quarterly Chart

    Clovis Oncology Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 3.218M
    Dec. 31, 2012 2.771M
    Sept. 30, 2012 2.762M
    June 30, 2012 2.68M
    March 31, 2012 2.425M
    Dec. 31, 2011 2.036M
    Sept. 30, 2011 1.714M
       
    June 30, 2011 1.705M
    March 31, 2011 1.405M
    Dec. 31, 2010 1.237M
    Sept. 30, 2010 1.083M
    June 30, 2010 1.152M
    March 31, 2010 0.83M

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    CLVS SG&A Expense Quarterly Benchmarks

    Companies
    Coronado Biosciences 2.681M
    Halozyme Therapeutics 6.979M
    Infinity Pharmaceuticals 7.111M

    CLVS SG&A Expense Quarterly Rankings

    Overall 51st percentile
    3852 of 8006
    Sector 44th percentile
    382 of 686 in Healthcare
    Industry 59th percentile
    101 of 248 in Biotechnology

    CLVS SG&A Expense Quarterly Range, Past 5 Years

    Minimum 0.8300M Mar 2010
    Maximum 3.218M Mar 2013
    Average 1.924M